

Pharma-Bio Serv, Inc.  
Form 8-K  
June 29, 2018

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT  
TO SECTION 13 or 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 29, 2018

Pharma-Bio Serv, Inc.  
(Exact Name of Registrant as Specified in Its Charter)

Delaware  
(State or Other Jurisdiction of Incorporation)

0-50956                                      20-0653570  
(Commission File Number) (I.R.S. Employer Identification No.)

6 Road 696, Dorado, Puerto Rico                      00646  
(Address of Principal Executive Offices) (Zip Code)

(787) 278-2709  
(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b2 of the Securities Exchange Act of 1934 (17 CFR §240.12b2).

Emerging growth company

Edgar Filing: Pharma-Bio Serv, Inc. - Form 8-K

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 29, 2018, Pharma-Bio Serv, Inc. (the “Company”) held its 2018 Annual Meeting of Stockholders. Below is a summary of the proposals and corresponding votes.

Kirk Michel and Dov Perlysky were elected as Class II directors to serve for a term until the 2021 Annual Meeting of Stockholders or until successors are duly elected and qualified. Kirk Michel and Dov Perlysky received the following votes:

| Nominee      | For        | Withheld |
|--------------|------------|----------|
| Kirk Michel  | 13,852,866 | 53,000   |
| Dov Perlysky | 13,852,866 | 53,000   |

There were 4,942,634 broker non-votes on this proposal.

The ratification of the selection of Horwath Velez & Co. PSC as the Company's independent certified public accountants for the fiscal year ending October 31, 2018 received the following votes:

| For        | Against | Abstain |
|------------|---------|---------|
| 18,819,557 | 0       | 28,943  |

There were no broker non-votes on this proposal.



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PHARMA-BIO SERV, INC.

Date: June 29, 2018 By: /s/ Pedro J. Lasanta  
Pedro J. Lasanta  
Chief Financial Officer, Vice President Finance and  
Administration and Secretary